Last reviewed · How we verify

Instituto de Olhos de Goiania — Portfolio Competitive Intelligence Brief

Instituto de Olhos de Goiania pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Aflibercept and ranibizumab Aflibercept and ranibizumab marketed Anti-VEGF agent VEGF-A (and VEGF-B for aflibercept) Ophthalmology
Ranibizumab and Aflibercept Ranibizumab and Aflibercept marketed Anti-VEGF agent VEGF-A (vascular endothelial growth factor-A) Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. University Hospital, Basel, Switzerland · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Instituto de Olhos de Goiania:

Cite this brief

Drug Landscape (2026). Instituto de Olhos de Goiania — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/instituto-de-olhos-de-goiania. Accessed 2026-05-17.

Related